Leadership Turmoil and Strategic Challenges at Novo Nordisk

The Danish pharmaceutical giant Novo Nordisk finds itself navigating its most significant corporate crisis in recent memory. A dramatic sequence of events has unfolded, casting uncertainty over the company’s governance and strategic direction just as competitive pressures intensify.

In a surprising turn of events, Mikael Dolsten, the former head of research at rival firm Pfizer, withdrew his candidacy for Novo Nordisk’s supervisory board on the eve of an extraordinary general meeting scheduled for November 14. The official reason cited was “personal circumstances,” but the timing raises significant questions. The withdrawal occurred shortly after Pfizer outmaneuvered Novo Nordisk in the billion-dollar bidding contest for biotechnology firm Metsera, highlighting the intense rivalry between the Read more...